Skip to main content

Pacira BioSciences Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

PCRX$36.49+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome
Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total
Balance at June 30, 202446,954(837)$47$(25,121)$983,178$(78,931)$105$879,278
Vested restricted stock units31———————
Common stock withheld for employee withholding tax liabilities on vested restricted stock units————(32)——(32)
Stock-based compensation————13,230——13,230
Other comprehensive income (Note 10)——————573573
Net loss—————(143,466)—(143,466)
Balance at September 30, 202446,985(837)$47$(25,121)$996,376$(222,397)$678$749,583
Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveLoss
Shares · Amount · Total
Balance at June 30, 202346,409$46$950,626$(142,524)$(173)$807,975
Exercise of stock options1—25——25
Vested restricted stock units17—————
Stock-based compensation——12,530——12,530
Other comprehensive income (Note 10)————163163
Net income———10,858—10,858
Balance at September 30, 202346,427$46$963,181$(131,666)$(10)$831,551

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

Number of Shares Outstanding · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome
Common Shares · Treasury Shares · Common Stock · Treasury Stock · Total
Balance at December 31, 202346,481—$46$—$976,633$(106,796)$247$870,130
Vested restricted stock units448—1————1
Common stock withheld for employee withholding tax liabilities on vested restricted stock units————(414)——(414)
Common stock issued under employee stockpurchase plan56———1,364——1,364
Stock-based compensation————38,905——38,905
Purchase of treasury stock, inclusive of excise tax—(837)—(25,121)———(25,121)
Purchase of capped call transaction, net of tax————(20,112)——(20,112)
Other comprehensive income (Note 10)——————431431
Net loss—————(115,601)—(115,601)
Balance at September 30, 202446,985(837)$47$(25,121)$996,376$(222,397)$678$749,583
Common Stock · AdditionalPaid-InCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveLoss
Shares · Amount · Total
Balance at December 31, 202245,928$46$924,095$(148,751)$(380)$775,010
Exercise of stock options63—1,939——1,939
Vested restricted stock units386—————
Common stock issued under employee stockpurchase plan50—1,672——1,672
Stock-based compensation——35,475——35,475
Other comprehensive income (Note 10)————370370
Net income———17,085—17,085
Balance at September 30, 202346,427$46$963,181$(131,666)$(10)$831,551
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.